Welcome to our dedicated page for Joint SEC filings (Ticker: JYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the metrics that really move Joint Corp—clinic count growth, franchise royalties, or membership churn? This page brings every SEC disclosure together so you can stop hunting and start understanding. Whether you need the Joint Corp insider trading Form 4 transactions or the latest Joint Corp quarterly earnings report 10-Q filing, Stock Titan delivers them the moment they hit EDGAR.
Our AI engine reads each document line-by-line and serves plain-English answers. Think of it as "Joint Corp SEC filings explained simply"—from a 300-page 10-K to a one-page 8-K. Click any filing type below and you’ll see auto-generated key points, ratio calculations, and trend charts:
- Joint Corp annual report 10-K simplified—franchise economics, clinic openings, risk factors
- Joint Corp Form 4 insider transactions real-time—alerts on executive buys and sells
- Joint Corp proxy statement executive compensation—bonus targets tied to same-store sales
- Joint Corp 8-K material events explained—new market entries or leadership updates
Need deeper context? Our "understanding Joint Corp SEC documents with AI" module cross-links sections so you can compare revenue per clinic across multiple quarters. For quick takeaways, the "Joint Corp earnings report filing analysis" highlights margin shifts and patient visit growth. Professionals monitoring Joint Corp executive stock transactions Form 4 can set real-time alerts to spot patterns before the market reacts.
Every document, every detail, always current—because informed decisions start with complete, clear data.
The reporting person, Christopher M. Grandpre, a director of The Joint Corp. (JYNT), purchased 10,000 shares of the issuer's common stock on 08/20/2025 at a weighted-average price of $10.4082 per share. After the reported acquisition, the reporting person beneficially owns 39,383 shares in total. The filing was signed by an attorney-in-fact on 08/22/2025. The footnote clarifies the reported price is a weighted average covering multiple purchases at prices ranging from $10.30 to $10.57, and the reporting person will provide breakdowns on request.
Charles E. Jobson filed an amended Schedule 13G reporting beneficial ownership of 1,075,994 shares of JOINT Corp common stock (CUSIP 47973J102), representing 7.01% of the class. The filing states Mr. Jobson has sole voting and sole dispositive power over all reported shares, and no shared voting or dispositive arrangements are reported. The document lists JOINT Corp's principal executive office in Scottsdale, Arizona, and Mr. Jobson's residence in Wellesley, Massachusetts. No group affiliations, subsidiaries, or holdings on behalf of others are reported, and certification language attests to the accuracy of the statement.
Christopher M. Grandpre, a director of The Joint Corp. (JYNT), reported two open-market purchases of the issuer's common stock in mid-August 2025. The filing shows a purchase of 14,388 shares on 08/15/2025 at a weighted average price of $10.8793 and a subsequent purchase of 10,000 shares on 08/18/2025 at a weighted average price of $10.6978. Following these transactions he beneficially owned 29,383 shares as a direct owner. The filing was submitted under a Form 4 and signed by an attorney-in-fact on 08/19/2025. No derivative transactions, dispositions, or additional contextual details about the purpose of the purchases are provided in this document.
Schedule 13G filing overview – The Joint Corp. (JYNT)
On 10 July 2025, Skylands Capital, LLC, a Wisconsin-based investment adviser, submitted a Schedule 13G reporting its beneficial ownership in The Joint Corp. common stock. The filing relates to an event dated 30 June 2025.
- Shares owned: 779,295
- % of outstanding class: 5.1%
- Voting power: Sole power to vote and dispose of all reported shares; no shared power
- Filing basis: Rule 13d-1(b) – passive investment by an investment adviser (IA)
- Intent statement: Securities acquired and held in the ordinary course, not for the purpose of influencing control
The disclosure means Skylands has crossed the 5 % reporting threshold, giving investors fresh insight into institutional ownership dynamics at The Joint Corp. No other entities or group relationships are identified, and there are no indications of activist intent.
Joint (NASDAQ:JYNT) agreed to sell the assets of 31 company-owned clinics in Arizona and New Mexico to Joint Ventures, LLC for $11.07 million, with closing targeted on or before 30 Jun 2025 and customary conditions attached. In return, the company will obtain regional developer rights covering 46 existing franchised clinics and 30 future development sites across Northern California, Utah, Nevada, Washington and Oregon, enlarging its franchise pipeline.
In a separate transaction, the company divested five clinics in Kansas and Missouri to 93 Chiro, LLC. Management positions both deals as part of a strategic shift toward an asset-light, royalty-driven model that increases liquidity, cuts operating costs and accelerates unit growth.
FAQ
What is the current stock price of Joint (JYNT)?
What is the market cap of Joint (JYNT)?
